Ten-Year Follow-Up of a Patient with Pacemaker Induced Superior Vena Cava Syndrome

1997 ◽  
Vol 20 (6) ◽  
pp. 1734-1736 ◽  
Author(s):  
HAJIME KATAOKA
Keyword(s):  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Vena Cava Syndrome

scholarly journals Endovascular therapy of acute tumour-related obstruction of the superior vena cava using a self-expanding Nitinol stent

2013 ◽  
Vol 17 (4) ◽  
pp. 123-127
Author(s):  
Peter Kamusella ◽  
Christian Wissgott ◽  
Reimer Andresen
Keyword(s):  
Superior Vena Cava ◽  
Endovascular Therapy ◽  
Superior Vena Cava Syndrome ◽  
Tumour Progression ◽  
Superior Vena ◽  
Vena Cava ◽  
Bronchial Carcinoma ◽  
Nitinol Stent ◽  
Vena Cava Syndrome

Objective: To evaluate, in a retrospective study, the clinical efficacy and safety of the self-expanding Nitinol stent in the superior vena cava to alleviate upper venous congestion.Method: In 22 patients (15 men, 7 women), a tumour-related compression of the superior vena cava was diagnosed by spiral CT after intravenous application of contrast medium. Clinically, acute superior vena cava syndrome was found in all patients. Histologically, a bronchial carcinoma was present in 14/22, a lymphoma in 6/22, and mediastinal lymphnode metastases (1 breast carcinoma, 1 malignant melanoma) in 2/22. After a transfemoral approach, cavography was initially performed. The degree of stenosis was classified according to the Stanford classification. In accordance with the degree of stenosis, a self-expanding Nitinol stent was placed.Results: Endovascular stent implantation was conducted without complications in all patients. A marked improvement in acute symptoms was observed clinically within 24 hours in all patients. In the follow-up period of up to 2 years, there were no cases of stent migration. In 7/22 patients, the CT follow-ups revealed tumour progression (3/7 after 3 months, 2/7 after 6 months, and 2/7 after 12 months) with evidence of residual stenosis caused by tumour growth through the stent mesh. During the follow-up period, 15/22 patients died (mean survival 6.4 months).Conclusion: Self-expanding Nitinol stents provide endovascular therapy for superior vena cava syndrome, having a high radial expansive force and the facility to be placed precisely, and alleviating acute, life-threatening symptoms in the palliative situation.

Pacemaker-Induced Superior Vena Cava Syndrome: Clinical Evaluation of Long-Term Follow-Up

2006 ◽  
Vol 29 (12) ◽  
pp. 1346-1351 ◽  
Author(s):  
CHRISTOPH MELZER ◽  
ALEXANDER LEMBCKE ◽  
SABINE ZIEMER ◽  
STEPHAN EDDICKS ◽  
JOACHIM WITTE ◽  
...  
Keyword(s):  
Superior Vena Cava ◽  
Clinical Evaluation ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Long Term Follow Up ◽  
Vena Cava Syndrome

Superior vena cava syndrome associated with Behcet’s disease and 18 months’ follow up: a case report

2008 ◽  
Vol 28 (8) ◽  
pp. 807-809 ◽  
Author(s):  
Ilhan Sezer ◽  
M. Alkan Melikoglu ◽  
H. Fatih Çay ◽  
Hilal Kocabaş ◽  
Bülent Bütün
Keyword(s):  
Case Report ◽  
Superior Vena Cava ◽  
Behcet’S Disease ◽  
Superior Vena Cava Syndrome ◽  
Behçet's Disease ◽  
Superior Vena ◽  
Vena Cava ◽  
Behcet's Disease ◽  
Vena Cava Syndrome

scholarly journals Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Haitao Liu ◽  
Yahua Li ◽  
Yang Wang ◽  
Lei Yan ◽  
Pengli Zhou ◽  
...  
Keyword(s):  
Superior Vena Cava ◽  
Stent Placement ◽  
Superior Vena Cava Syndrome ◽  
Clinical Symptoms ◽  
Malignant Tumors ◽  
Superior Vena ◽  
Vena Cava ◽  
Tumor Type ◽  
Vena Cava Syndrome

Abstract Objectives To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors. Methods We retrospectively analyzed the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatment in our department from 2015 to 2019 due to malignant tumors and summarized the patient’s sex, age, tumor type, endovascular treatment plan, complications and postoperative follow-up. Results All patients successfully underwent percutaneous intraluminal stent placement with digital subtraction angiography (DSA). Thirty-seven endovascular stents were implanted in 32 patients, including 21 Eluminexx stents, 12 Wallstent stents and 4 covered stents. The technical success rate was 100%, and there were no serious surgery-related complications. The remission rate of clinical symptoms was 53.1% (17/32) at 24 h and 84.4% (27/32) at 48 h. After 48 h, the symptoms of the remaining patients were slowly relieved, and the symptom relief rate was 100% at 7 days. The follow-up period was 1.5–24 months, with an average follow-up period of 6.5 months. During the follow-up, 3 patients had restenosis and 1 patient had secondary thrombosis in the stent. Their symptoms were relieved after the second treatment. Conclusion For superior vena cava syndrome caused by malignant tumors, percutaneous endoluminal stent therapy can quickly and effectively relieve the clinical symptoms of patients, and the incidence of complications is low.

scholarly journals Percutaneous Transluminal Stenting for Superior Vena Cava Syndrome Caused by Malignant Tumors : A Single Center Retrospective Study

2020 ◽  
Author(s):  
Haitao Liu ◽  
Yahua Li ◽  
Yang Wang ◽  
Lei Yan ◽  
Pengli Zhou ◽  
...  
Keyword(s):  
Superior Vena Cava ◽  
Stent Placement ◽  
Superior Vena Cava Syndrome ◽  
Clinical Symptoms ◽  
Malignant Tumors ◽  
Superior Vena ◽  
Vena Cava ◽  
Tumor Type ◽  
Vena Cava Syndrome

Abstract Objectives：To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors.Methods：To retrospectively analyze the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatment in our department from 2015 to 2019 due to malignant tumors, and summarize the patient’s gender, age, tumor type, endovascular treatment plan, complications and postoperative follow-up.Results：All patients successfully underwent percutaneous intraluminal stent placement with digital subtraction angiography (DSA). Thirty seven endovascular stents were implanted in 32 patients, including 21 Eluminexx stents, 12 Wallstent stents, and 4 covered stents..The technical success rate was 100%, and there were no serious surgery-related complications.The remission rate of clinical symptoms was 53.1% (17 / 32) in 24 hours and 84.4% (27 / 32) in 48 hours. The follow-up period was 1.5-24 months, with an average follow-up period of 6.5 months. During the follow-up, 3 patients had re-stenosis and 1 patient had secondary thrombosis in the stent. The symptoms were relieved after the second treatment.Conclusion: For superior vena cava syndrome caused by malignant tumors, percutaneous endoluminal stent therapy can quickly and effectively relieve the clinical symptoms of patients, and the incidence of complications is low. It should be used as a first-line treatment.

scholarly journals Superior Vena Cava Syndrome due to pericardial hematoma: A case report and mini-review of literature

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110577
Author(s):  
Aninka Saboe ◽  
Andra Naufal Pramanda ◽  
Melawati Hasan ◽  
Nuraini Yasmin Kusumawardhani ◽  
Euis Maryani ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Atrial Septal Defect Closure ◽  
Chronic Expanding Hematoma ◽  
Vena Cava Syndrome ◽  
The Right

Superior vena cava syndrome is a life-threatening condition. Typically, the clinical presentations are gradual; hence, the diagnosis is often delayed until critical compression or obstruction has occurred. Pericardial hematoma is a rare condition that could occur after cardiac surgery. An asymptomatic, 25-year-old female, who underwent surgical atrial septal defect closure 5 days ago, was sent for routine echocardiography examination before discharge. An intrapericardiac hematoma was detected at the right atrium’s free wall without any intracardiac hemodynamic consequences. The patient was discharged and planned for monthly evaluation. During follow-up, the intrapericardiac hematoma was expanding. In the third month’s follow-up, the patient complained of shortness of breath, headaches, and coughs. Echocardiography evaluation revealed enlarged pericardial hematoma, which compressed the right atrium and superior vena cava orifice, without echo’ sign of cardiac tamponade. Computed tomography scan revealed superior vena cava compression by the pericardial hematoma and appearance of the collateral vessel. The patient was diagnosed with superior vena cava syndrome and sent for surgical evacuation. Pericardial hematoma after cardiac surgery should be evaluated meticulously. Chronic expanding hematoma could cause superior vena cava syndrome, which is fatal. Early diagnosis and appropriate treatment are essential in managing this condition.

scholarly journals Percutaneous salvage interventions in the Glenn circuit: a case series

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Aritra Mukherji ◽  
Sanjiban Ghosh ◽  
Jayita Nandi Das ◽  
Amitabha Chattopadhyay
Keyword(s):  
Pulmonary Artery ◽  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Left Pulmonary Artery ◽  
Glenn Shunt ◽  
Bidirectional Glenn ◽  
Vena Cava Syndrome

Abstract Background In majority of children bidirectional Glenn shunt is a safe and efficacious procedure with minimal post-operative issues. Rarely, there may be dysfunction in the Glenn pathway due loss of anatomical integrity or derangements in normal physiological or hemodynamic milieu. We report 4 cases in the last 3 years (2016-2019) where complications in the Glenn circuit led to serious consequences requiring transcatheter interventions. Case presentation Two of our patients presented with frank features of superior vena cava syndrome. One of them had right Glenn anastomotic site narrowing leading to severe obstruction along with significant left pulmonary artery origin stenosis. The other child had excessive antegrade flow impeding normal Glenn flow leading to superior vena cava syndrome. The next child in our series was initially lost to follow-up after bidirectional Glenn surgery. Later on, this child was noted to have discontinuous left pulmonary artery with perfusion only to the right lung from the Glenn. The remaining child described in this series had developed a large tortuous venous collateral post Glenn shunt leading to severe cyanosis. All the above children needed prompt percutaneous interventions to revert back to their basal state. On follow-up, the benefit was sustained in all. Conclusions Percutaneous intervention procedures often provide a successful bailout option in various complicated situations post Glenn surgery with reasonable efficacy and safety.

Sign in / Sign up

Export Citation Format

Share Document